CliffBio
small molecule

LIVDELZI

SELADELPAR LYSINE

Loss of exclusivityMarch 2035latest FDA-listed patent expiry
CompanyGilead Sciences →View the full company profile on CliffBio

Drug detail

Brand nameLIVDELZI
Active ingredientSELADELPAR LYSINE
StrengthEQ 10MG BASE
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalAugust 2024
Marketing statusRX

Listed patents

PatentExpiresType
11596614March 2035use U-1854
11406611March 2035use U-1854
10272058March 2035use U-1854
9486428March 2035use U-1854
7709682September 2026substance
7301050August 2026substance, product

Regulatory exclusivity

CodeExpires
ODE-486August 2031
NCEAugust 2029

More from Gilead Sciences

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

LIVDELZI patent cliff — loss of exclusivity March 2035 | CliffBio